Adult Coats’ Disease Successfully Managed with the Dexamethasone Intravitreal Implant (Ozurdex®) Combined with Retinal Photocoagulation

PURPOSE To report a case of Coats' disease managed with the dexamethasone intravitreal implant Ozurdex(®) (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation. METHODS A 46-year-old female with 20/200 visual acuity was diagnosed with Coats' disease with secondary retinal vasoproliferative tumor. An initial approach was performed with an intravitreal injection of the sustained-release dexamethasone implant Ozurdex. After reattachment of the retina, the telangiectatic vessels were treated with laser photocoagulation. RESULTS The patient's visual acuity improved to 20/25 after the intravitreal Ozurdex. No further recurrences of exudation were evident through the 12-month follow-up. CONCLUSIONS Ozurdex may be an effective initial therapeutic approach for Coats' disease with immediate anatomical response and visual improvement.